MAIA Highlights Promising Phase 2 NSCLC Survival Outcomes

MAIA Biotechnology, Inc. ( (MAIA) ) has issued an update.

On March 31, 2026, MAIA Biotechnology reported that eight patients in its ongoing Phase 2 THIO-101 trial for non-small cell lung cancer achieved overall survival beyond two years when treated with ateganosine followed by cemiplimab. The data, presented March 27, 2026, at the European Lung Cancer Congress, included one third-line patient surviving 33 months versus an expected 5.8 months and four second-line patients exceeding 30 months versus a documented 10.5 months on standard care.

All eight patients had previously failed checkpoint inhibitor monotherapy and received no subsequent lines of therapy after the trial regimen, with five still in survival follow-up and an acceptable safety profile reported in this heavily pre-treated cohort. The results reinforce ateganosine’s potential role as a telomere-targeting priming agent that may enhance PD-(L)1 inhibitor effectiveness and support MAIA’s broader strategy to carve out a differentiated position in NSCLC immunotherapy as it advances THIO-101 and its ongoing Phase 3 program.

The most recent analyst rating on (MAIA) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on MAIA Biotechnology, Inc. stock, see the MAIA Stock Forecast page.

Spark’s Take on MAIA Stock

According to Spark, TipRanks’ AI Analyst, MAIA is a Neutral.

MAIA Biotechnology presents a mixed outlook. The company’s financial performance is weak due to its development-stage status and lack of revenue, contributing to a low financial performance score. However, recent positive trial results and technical indicators showing short-term upward momentum provide a more optimistic view. Valuation remains challenging due to negative earnings, but the potential for significant clinical advancements offers upside potential.

To see Spark’s full report on MAIA stock, click here.

More about MAIA Biotechnology, Inc.

MAIA Biotechnology, Inc. is a Chicago-based, clinical-stage biopharmaceutical company specializing in targeted immuno-oncology therapies for cancer. Its lead program, ateganosine (THIO), is a first-in-class telomere-targeting agent in development for non-small cell lung cancer (NSCLC) patients with telomerase-positive tumors, aiming to serve the multibillion-dollar global immunotherapy market.

The company focuses on developing and commercializing novel mechanisms of action intended to improve and extend the lives of patients with advanced cancers. Ateganosine is being positioned as a second- or later-line treatment option for NSCLC patients who have progressed beyond standard checkpoint inhibitor regimens, with clinical trials designed to enhance immune responses through sequential therapy.

Average Trading Volume: 1,074,010

Technical Sentiment Signal: Strong Sell

Current Market Cap: $79.48M

Find detailed analytics on MAIA stock on TipRanks’ Stock Analysis page.